Hormone Therapy

Testosterone replacement therapy increases 2 and 5 year reoperation rates after posterior lumbar fusion: a propensity-matched analysis of 1808 surgical patients.

TL;DR

Preoperative TRT use was not associated with increased short-term postoperative complications following posterior lumbar fusion but was independently associated with a significantly higher risk of long-term reoperation, with adjusted ORs of 2.36 at 2 years and 2.18 at 5 years.

Key Findings

Preoperative testosterone replacement therapy (TRT) use was independently associated with significantly higher odds of reoperation at 2 years after posterior lumbar fusion.

  • Adjusted OR 2.36 (95% CI 1.78–3.12, p < 0.001) at 2 years on multivariable analysis
  • Analysis was conducted after propensity-score matching 904 TRT users to 904 non-TRT users 1:1
  • Matching was based on age, Charlson Comorbidity Index (CCI), diabetes, and tobacco use
  • Total cohort included 5068 patients, of whom 955 were TRT users, identified from the PearlDiver Mariner165 database (2010–2020)

Preoperative TRT use was independently associated with significantly higher odds of reoperation at 5 years after posterior lumbar fusion.

  • Adjusted OR 2.18 (95% CI 1.70–2.80, p = 0.005) at 5 years on multivariable analysis
  • This finding persisted after adjusting for relevant comorbidities in multivariable logistic regression
  • TRT use was defined as ≥3 months of therapy with ≥2 prescriptions prior to surgery

There were no significant differences in 90-day postoperative complications between TRT users and non-TRT users following posterior lumbar fusion.

  • Outcomes assessed included acute kidney injury, thromboembolic events, surgical site complications, readmissions, and persistent pain
  • All 90-day complication comparisons had p > 0.05
  • The matched cohorts were well-balanced after propensity score matching on age, CCI, diabetes, and tobacco use
  • 904 matched pairs were analyzed from the full cohort of 5068 patients

The study identified 955 TRT users among 5068 adult male patients undergoing posterior lumbar fusion in a large administrative database spanning 2010–2020.

  • Data source was the PearlDiver Mariner165 database
  • Patients were identified using CPT codes for posterior lumbar fusion
  • Patients with major systemic or neurologic diseases were excluded
  • TRT cohort represented approximately 18.8% of the total identified population (955 of 5068)

The authors interpret TRT as potentially serving as a marker for patients with more complex postoperative trajectories rather than directly increasing perioperative risk.

  • Short-term (90-day) complication rates were similar between groups despite elevated long-term reoperation risk
  • The authors state 'TRT should not be considered a contraindication to surgery'
  • The authors suggest TRT presence 'may warrant closer longitudinal surveillance and more nuanced preoperative counseling regarding long-term expectations'
  • Proposed mechanisms include testosterone's known effects on bone metabolism, coagulation, and musculoskeletal physiology
  • The authors call for prospective studies incorporating radiographic and hormonal data to clarify underlying mechanisms

What This Means

This research suggests that men who were taking testosterone replacement therapy (TRT) before undergoing a type of spinal surgery called posterior lumbar fusion had a significantly higher chance of needing another operation within 2 and 5 years compared to men not on TRT. Specifically, TRT users were about 2.4 times more likely to require reoperation at 2 years and about 2.2 times more likely at 5 years. However, in the short term (within 90 days of surgery), TRT users did not experience more complications such as blood clots, kidney injury, wound infections, readmissions, or persistent pain than non-TRT users. The study used a large insurance claims database of over 5,000 male patients who had this type of spinal surgery between 2010 and 2020. To ensure a fair comparison, the researchers used a statistical technique called propensity-score matching to pair TRT users with similar non-TRT users based on age, overall health status, diabetes, and tobacco use, resulting in 904 matched pairs being analyzed. This research suggests that while TRT does not appear to make the immediate post-surgical period more dangerous, it may be linked to worse long-term outcomes after lumbar spine surgery. The authors propose that rather than directly causing complications, TRT use might signal that a patient has a more complex underlying condition that makes them more likely to need additional surgery down the road. Practically, these findings suggest that doctors may want to provide more detailed counseling to TRT users about long-term expectations after spinal fusion and consider closer follow-up monitoring, though TRT alone should not disqualify a patient from having the surgery.

Check Your Own Numbers

Upload your bloodwork. We'll cross-reference your results against this study and 4,700 others.

Upload Your Labs

Have a question about this study?

Citation

Sadh P, Warzecha H, Dassow M, Lewis A, Peresuh S, Carayannopoulos N, et al.. (2026). Testosterone replacement therapy increases 2 and 5&#xa0;year reoperation rates after posterior lumbar fusion: a propensity-matched analysis of 1808 surgical patients.. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. https://doi.org/10.1016/j.jocn.2026.112088